FIELD: medicine, pharmacy.
SUBSTANCE: invention proposes the developed methods for identification of compounds as possible candidates used for regulation of mass or function of skeletal muscles. Methods involve interaction of analyzed compound with receptors of corticotropin releasing factor-2. Also, invention describes a pharmaceutical composition and a method for treatment of skeletal muscles atrophy. Invention provides expanding assortment of agents designated for regulation of mass or function of skeletal muscles.
EFFECT: improved identifying methods.
35 cl, 1 tbl, 9 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGONISTS OF CORTICOTROPIN-RELEASING FACTOR (CRFR) RECEPTOR AND THEIR USING | 2003 |
|
RU2294333C2 |
| AGONISTS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR | 2003 |
|
RU2286995C2 |
| CORTICOTROPIN-RELEASING FACTOR RECEPTOR AGONISTS AND USES THEREOF | 2003 |
|
RU2305110C2 |
| UROCORTIN PROTEINS AND THEIR USING | 2001 |
|
RU2278871C2 |
| G-PROTEIN COUPLED RECEPTORS DROSOPHILA, NUCLEIC ACIDS AND RELATED METHODS | 2003 |
|
RU2326385C2 |
| COMPOSITIONS AND METHODS RELATED TO SOLUBLE G-PROTEIN CONJUGATE RECEPTORS (SGPCR) | 2006 |
|
RU2423378C2 |
| ANTIBODY AGAINST IGF-I RECEPTOR | 2018 |
|
RU2785305C2 |
| DPPIV-COGNATED NEW SERINE PROTEASE GENE | 2001 |
|
RU2305133C2 |
| TISSUE-SPECIFIC BIOMARKERS OF AGEING | 2010 |
|
RU2557313C2 |
| UROCORTIN-III, ITS ANALOG (VARIANTS) AND PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2305109C2 |
